TiGenix – American Depositary Shares (TIG) Lowered to “Hold” at Zacks Investment Research
TiGenix – American Depositary Shares (NASDAQ:TIG) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Saturday.
According to Zacks, “TiGenix NV is a biopharmaceutical company. It focused on developing and commercializing novel therapeutics for allogeneic or donor-derived, expanded stem cells. The company’s product platform consists of Cx601 and Cx611 which are in clinical trial stage. It operates primarily in Madrid, Spain. TiGenix NV is based in Leuven, Belgium. “
Several other equities research analysts have also issued reports on TIG. BidaskClub lowered shares of TiGenix – American Depositary Shares from a “hold” rating to a “sell” rating in a research note on Friday, October 27th. Canaccord Genuity reissued a “buy” rating and issued a $30.00 price objective (up previously from $22.00) on shares of TiGenix – American Depositary Shares in a research report on Wednesday, September 20th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $31.67.
An institutional investor recently bought a new position in TiGenix – American Depositary Shares stock. EAM Investors LLC acquired a new stake in TiGenix – American Depositary Shares (NASDAQ:TIG) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 155,886 shares of the company’s stock, valued at approximately $3,517,000. EAM Investors LLC owned 1.20% of TiGenix – American Depositary Shares at the end of the most recent reporting period. Institutional investors and hedge funds own 5.31% of the company’s stock.
TiGenix – American Depositary Shares Company Profile
TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TiGenix - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TiGenix - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.